Jazz Pharmaceuticals
JAZZ
427 hedge funds and large institutions have $7.37B invested in Jazz Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 185 increasing their positions, 116 reducing their positions, and 60 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 116
23% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 60
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more capital invested
Capital invested by funds: $6.52B → $7.37B (+$844M)
2% more funds holding
Funds holding: 417 → 427 (+10)
2.4% more ownership
Funds ownership: 88.02% → 90.42% (+2.4%)
29% less call options, than puts
Call options by funds: $26.5M | Put options by funds: $37.5M
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$110M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$56.2M |
| 3 |
Two Sigma Advisers
New York
|
+$42.6M |
| 4 |
JP Morgan Chase
New York
|
+$42.3M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$42M |
Top Sellers
JAZZ Hedge Fund Activity: Q1 2019 in Review
427 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2019, worth a combined $7.37B — up 13% from $6.52B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new JAZZ positions and 60 closed out — a net gain of 14 holders — while 185 added to existing stakes and 116 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $110M. The largest seller was Putnam Investments, cutting an estimated $234M.
- 427 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2019, up from 417 in Q4 2018.
- Funds reported $7.37B of Jazz Pharmaceuticals stock for Q1 2019, up 13% quarter-over-quarter.
- 74 funds opened new Jazz Pharmaceuticals positions in Q1 2019 and 60 closed out, a net change of +14 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2019 was Renaissance Technologies, an estimated $110M added.
- The largest Jazz Pharmaceuticals seller in Q1 2019 was Putnam Investments, an estimated $234M sold.
Based on aggregated 13F filings for Q1 2019.